238 related articles for article (PubMed ID: 33858190)
21. Feasibility and Outcome of a Phase II Study of Intensive Induction Chemotherapy in 91 Elderly Patients with AML Evaluated Using a Simplified Multidimensional Geriatric Assessment.
Capelli D; Saraceni F; Fiorentini A; Chiarucci M; Menotti D; Poloni A; Discepoli G; Leoni P; Olivieri A
Adv Ther; 2020 May; 37(5):2288-2302. PubMed ID: 32297279
[TBL] [Abstract][Full Text] [Related]
22. Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients.
Serio B; Grimaldi F; Ammirati L; Annunziata M; De Santis G; Perrotta A; De Novellis D; Giudice V; Morini D; Storti G; Califano C; Risitano AM; Pane F; Selleri C
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2044. PubMed ID: 38662362
[TBL] [Abstract][Full Text] [Related]
23. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.
Pilorge S; Rigaudeau S; Rabian F; Sarkozy C; Taksin AL; Farhat H; Merabet F; Ghez S; Raggueneau V; Terré C; Garcia I; Renneville A; Preudhomme C; Castaigne S; Rousselot P
Am J Hematol; 2014 Apr; 89(4):399-403. PubMed ID: 24375467
[TBL] [Abstract][Full Text] [Related]
24. Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.
Elsayed AH; Cao X; Mitra AK; Wu H; Raimondi S; Cogle C; Al-Mansour Z; Ribeiro RC; Gamis A; Kolb EA; Aplenc R; Alonzo TA; Meshinchi S; Rubnitz J; Pounds S; Lamba JK
J Clin Oncol; 2022 Mar; 40(7):772-783. PubMed ID: 34990262
[TBL] [Abstract][Full Text] [Related]
25. Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study.
Ito Y; Wakita A; Takada S; Mihara M; Gotoh M; Ohyashiki K; Ohtake S; Miyawaki S; Ohnishi K; Naoe T
Int J Hematol; 2012 Oct; 96(4):485-91. PubMed ID: 22956429
[TBL] [Abstract][Full Text] [Related]
26. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.
Gamis AS; Alonzo TA; Meshinchi S; Sung L; Gerbing RB; Raimondi SC; Hirsch BA; Kahwash SB; Heerema-McKenney A; Winter L; Glick K; Davies SM; Byron P; Smith FO; Aplenc R
J Clin Oncol; 2014 Sep; 32(27):3021-32. PubMed ID: 25092781
[TBL] [Abstract][Full Text] [Related]
27. Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis.
Xu Q; He S; Yu L
Front Immunol; 2021; 12():683595. PubMed ID: 34484181
[TBL] [Abstract][Full Text] [Related]
28. Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials.
Li X; Xu SN; Qin DB; Tan Y; Gong Q; Chen JP
Ann Oncol; 2014 Feb; 25(2):455-61. PubMed ID: 24478322
[TBL] [Abstract][Full Text] [Related]
29. Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study.
Walter RB; Medeiros BC; Gardner KM; Orlowski KF; Gallegos L; Scott BL; Hendrie PC; Estey EH
Haematologica; 2014 Jan; 99(1):54-9. PubMed ID: 24142996
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of adding gemtuzumab ozogamicin to conventional chemotherapy for adult acute myeloid leukemia: a systematic review and meta-analysis.
Guo Y; Deng L; Qiao Y; Liu B
Hematology; 2022 Dec; 27(1):53-64. PubMed ID: 34957930
[No Abstract] [Full Text] [Related]
31. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
de Witte T; Suciu S; Meert L; Halkes C; Selleslag D; Bron D; Amadori S; Willemze R; Muus P; Baron F
Ann Hematol; 2015 Dec; 94(12):1981-9. PubMed ID: 26410352
[TBL] [Abstract][Full Text] [Related]
32. Anthracycline dose intensification in acute myeloid leukemia.
Fernandez HF; Sun Z; Yao X; Litzow MR; Luger SM; Paietta EM; Racevskis J; Dewald GW; Ketterling RP; Bennett JM; Rowe JM; Lazarus HM; Tallman MS
N Engl J Med; 2009 Sep; 361(13):1249-59. PubMed ID: 19776406
[TBL] [Abstract][Full Text] [Related]
33. Outcomes in patients treated with gemtuzumab ozogamicin for relapsed acute myelogenous leukemia.
Lang K; Menzin J; Earle CC; Mallick R
Am J Health Syst Pharm; 2002 May; 59(10):941-8. PubMed ID: 12040733
[TBL] [Abstract][Full Text] [Related]
34. Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group.
Niktoreh N; Lerius B; Zimmermann M; Gruhn B; Escherich G; Bourquin JP; Dworzak M; Sramkova L; Rossig C; Creutzig U; Reinhardt D; Rasche M
Haematologica; 2019 Jan; 104(1):120-127. PubMed ID: 30093401
[TBL] [Abstract][Full Text] [Related]
35. Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.
Röllig C; Kramer M; Gabrecht M; Hänel M; Herbst R; Kaiser U; Schmitz N; Kullmer J; Fetscher S; Link H; Mantovani-Löffler L; Krümpelmann U; Neuhaus T; Heits F; Einsele H; Ritter B; Bornhäuser M; Schetelig J; Thiede C; Mohr B; Schaich M; Platzbecker U; Schäfer-Eckart K; Krämer A; Berdel WE; Serve H; Ehninger G; Schuler US;
Ann Oncol; 2018 Apr; 29(4):973-978. PubMed ID: 29390048
[TBL] [Abstract][Full Text] [Related]
36. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.
Burnett AK; Hills RK; Milligan D; Kjeldsen L; Kell J; Russell NH; Yin JA; Hunter A; Goldstone AH; Wheatley K
J Clin Oncol; 2011 Feb; 29(4):369-77. PubMed ID: 21172891
[TBL] [Abstract][Full Text] [Related]
37. Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia.
Fianchi L; Pagano L; Leoni F; Storti S; Voso MT; Valentini CG; Rutella S; Scardocci A; Caira M; Gianfaldoni G; Leone G
Ann Oncol; 2008 Jan; 19(1):128-34. PubMed ID: 17906298
[TBL] [Abstract][Full Text] [Related]
38. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial.
Burnett A; Cavenagh J; Russell N; Hills R; Kell J; Jones G; Nielsen OJ; Khwaja A; Thomas I; Clark R;
Haematologica; 2016 Jun; 101(6):724-31. PubMed ID: 26921360
[TBL] [Abstract][Full Text] [Related]
39. Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?
Paubelle E; Ducastelle-Leprêtre S; Labussière-Wallet H; Nicolini FE; Barraco F; Plesa A; Salles G; Wattel E; Thomas X
Ann Hematol; 2017 Mar; 96(3):363-371. PubMed ID: 28011984
[TBL] [Abstract][Full Text] [Related]
40. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]